CD274 and neoplasm: Since the emergence of immune checkpoint inhibitors (ICIs) that target the programmed death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) axis, there has been growing evidence that patients with DNA mismatch repair (dMMR)/microsatellite instability‐high (MSI‐H) CRC and those with a high tumor mutational burden (TMB) can greatly benefit from ICI treatment.2, 3